Forest Laboratories — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
memantine ERThe objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).	Alzheimer	Phase 3	À vérifier	United States, Argentina, Chile, Mexico	À vérifier
memantine ERThe objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).	Alzheimer	Phase 3	À vérifier	United States, Argentina, Chile, Mexico	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
memantine ER	Alzheimer	Phase 3	NCT00322153	A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease	COMPLETED

Publications

3

Molécule	Indication / population	Titre	Journal	Date
memantine ER		Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension.	Journal of child and adolescent psychopharmacology
memantine ER		Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.	Alzheimer disease and associated disorders
memantine ER		An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.	Expert opinion on pharmacotherapy